Skip to content

UroGen Pharma Ltd

US · URGN #2773 by market cap Listed 2017
27.65 -4.08 -12.86%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 16 in the most recent period (2026/Q3).
  • Total institutional ownership rose 2.4 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
101.87% +2.35pp
Institutions
246 +16
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund36.10%
Hedge Fund31.83%
Public Company19.06%
VC/PE Fund9.15%
Private Company4.40%
Individual/Insider1.89%
Government Pension Fund1.07%
Insurance Company0.21%
Other2.09%

Top holders as of 2026-06-30

RTW Investments, LP 9.26% · 4.54M sh
The Toronto-Dominion Bank 6.87% · 3.37M sh
BlackRock 6.24% · 3.06M sh
Kynam Capital Management, LP 4.96% · 2.43M sh
Jefferies Financial Group Inc. 4.48% · 2.20M sh
Morgan Stanley 4.43% · 2.17M sh
Morgan Stanley Investment Management Inc. 4.43% · 2.17M sh
SG Americas Securities, LLC 4.19% · 2.05M sh
American Century Investment Management 3.45% · 1.69M sh
Acorn Bioventures 3.41% · 1.67M sh
Point72 Asset Management, L.P. 3.11% · 1.53M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 31 buys · 19 sells

NameRoleStake
Arie Belldegrun Independent Chairperson 0.83%
Elizabeth Barrett Chief Executive Officer 0.67%
Mark Schoenberg Chief Medical Officer 0.12%
Jason Smith General Counsel, Chief Compliance Officer & Corporate Secretary 0.11%
Dong Kim Former Chief Financial Officer 0.09%
Fred Cohen Former Independent Director 0.03%
James Robinson Independent Director 0.02%
Christopher Degnan Chief Financial Officer 0.01%
Stuart Holden Independent Director 0.00%
Cynthia Butitta Independent Director 0.00%
Leana Wen Independent Director 0.00%
Daniel Wildman Independent Director 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-07 Christopher Degnan Chief Financial Officer Derivative Exercise and Sale -2,202 $36.69
2026-10-07 Christopher Degnan Chief Financial Officer Derivative Exercise and Retained +2,281 --
2026-09-07 Mark Schoenberg Chief Medical Officer Derivative Exercise and Sale -871 $42.92
2026-09-07 Mark Schoenberg Chief Medical Officer Intent to Sell (Form 144) -871 $44.09
2026-09-07 Jason Smith General Counsel, Chief Compliance Officer & Corporate Secretary Derivative Exercise and Sale -1,519 $42.54
2026-09-07 Jason Smith General Counsel, Chief Compliance Officer & Corporate Secretary Intent to Sell (Form 144) -1,519 $44.09
2026-09-06 Mark Schoenberg Chief Medical Officer Derivative Exercise and Retained +796 --
2026-09-06 Jason Smith General Counsel, Chief Compliance Officer & Corporate Secretary Derivative Exercise and Retained +1,815 --
2026-08-25 James Robinson Independent Director Derivative Exercise and Retained +2,000 --
2026-08-19 Mark Schoenberg Chief Medical Officer Open Market Disposition -60,677 $47.05
2026-07-08 Mark Schoenberg Chief Medical Officer Automatic Disposition -10,000 $40.00
2026-06-21 Cynthia Butitta Independent Director Other Derivative Acquisition +8,000 --
2026-06-21 Cynthia Butitta Independent Director Other Derivative Acquisition +10,000 $34.99
2026-06-21 Stuart Holden Independent Director Other Derivative Acquisition +20,000 $34.99
2026-06-21 Arie Belldegrun Independent Chairperson Other Derivative Acquisition +20,000 $34.99
2026-06-21 Daniel Wildman Independent Director Other Derivative Acquisition +8,000 --
2026-06-21 Daniel Wildman Independent Director Other Derivative Acquisition +10,000 $34.99
2026-06-21 Mark Schoenberg Chief Medical Officer Automatic Disposition -10,000 $35.01
2026-06-21 James Robinson Independent Director Other Derivative Acquisition +8,000 --
2026-06-21 James Robinson Independent Director Other Derivative Acquisition +10,000 $34.99

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.

UroGen Pharma Ltd discussion 0 comments

Add a comment